1
|
Zuo Y, Long Z, Li R, Le Y, Zhang S, He H, Yan L. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation. Eur J Med Chem 2024; 265:116106. [PMID: 38169271 DOI: 10.1016/j.ejmech.2023.116106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 12/26/2023] [Accepted: 12/26/2023] [Indexed: 01/05/2024]
Abstract
Clinical researches have shown that epidermal growth factor receptor (EGFR) is a key target for treatment of non-small cell lung cancer (NSCLC). Many EGFR inhibitors were successfully developed as ani-tumor drugs to treat NSCLC patients. Unfortunately, drug resistances were found in clinic. To overcome C797S mutation in EGFR, a novel series of 4-arylamine substituted pyrimidine derivatives were designed and synthesized under the principle of structure-based drug design. Interestingly, compounds 6e and 9i demonstrated the best anti-proliferative activity against A549, NCI-H1975, and HCC827 cells. In particular, the IC50 values against HCC827 cells reached to 24.6 nM and 31.6 nM, which were much lower than human normal cells 2BS and LO2. Furthermore, compounds 6e and 9i showed extraordinary activity against EGFR19del/T790M/C797S (IC50 = 16.06 nM and 37.95 nM) and EGFRL858R/T790M/C797S (IC50 = 11.81 nM and 26.68 nM), which were potent than Osimertinib (IC50 = 52.28 nM and 157.60 nM). Further studies have shown that compounds 6e and 9i could pertain inhibition of HCC827 colony formation, and arrest HCC827 cells at G2/M phase. Moreover, the most promising compound 6e could inhibit the migration of HCC827 cells, induce HCC827 cells apoptosis, and significantly inhibit the phosphorylation of EGFR, AKT and Erk1/2. In vivo xenograft mouse model with HCC827 cells, compound 6e resulted in remarkable tumor regression without obvious toxicity. In addition, molecular docking studies suggested that compound 6e could firmly combine with T790M-mutant, T790 M/C797S-mutant, and L858R/T790 M/C797S-mutant EGFR kinases as ATP-competitive inhibitor.
Collapse
Affiliation(s)
- Yaqing Zuo
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Zhiwu Long
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Rongrong Li
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Yi Le
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China
| | - Silong Zhang
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Huan He
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Longjia Yan
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.
| |
Collapse
|
2
|
Dhiwar PS, Purawarga Matada GS, Pal R, Singh E, Ghara A, Maji L, Sengupta S, Andhale G. An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review. J Biomol Struct Dyn 2024; 42:1564-1581. [PMID: 37158086 DOI: 10.1080/07391102.2023.2204351] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 03/30/2023] [Indexed: 05/10/2023]
Abstract
Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor receptor 2 (HER2) gets activated when its endogenous ligand(s) bind to its ATP binding site of target receptors. In breast cancer (BC), EGFR and HER2 are two proteins are overexpressed which leads to overexpression of cells proliferation and decreases cell death/apoptosis. Pyrimidine is one of the most widely studied heterocyclic scaffolds for EGFR as well as HER2 inhibition. We gather some remarkable results for fused-pyrimidine derivatives on various cancerous cell lines (in-vitro) and animal (in-vivo) evaluation to highlight their potency. The heterocyclic (five, six-membered, etc.) moieties which are coupled with pyrimidine moiety are potent against EGFR and HER2 inhibitions. Hence structure-activity relationship (SAR) plays important role in study of heterocyclic moiety along pyrimidine and effects of substituents, groups for increase or decrease in the cancerous activity and toxicity. By thoughtful of fused pyrimidines SAR study, it facilitates in receiving excellent overview of the compounds by concerning of efficacy and potential summary for future EGFR inhibitors. Furthermore, we studied the in-silico interactions of synthesized compounds to evaluate binding affinity towards the key amino acids..Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Prasad Sanjay Dhiwar
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | | | - Rohit Pal
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | - Ekta Singh
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | - Abhishek Ghara
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | - Lalmohan Maji
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | - Sindhuja Sengupta
- Intergrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
| | - Ganesh Andhale
- Department of Pharmaceutical Chemistry, Alard College of Pharmacy, Pune, India
| |
Collapse
|
3
|
Xu F, Zhang X, Chen Z, He S, Guo J, Yu L, Wang Y, Hou C, Ai-Furas H, Zheng Z, Smaill JB, Patterson AV, Zhang ZM, Chen L, Ren X, Ding K. Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. J Med Chem 2022; 65:14032-14048. [PMID: 36173763 DOI: 10.1021/acs.jmedchem.2c01246] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
EGFR inhibitor therapies have brought significant benefit to NSCLC patients. However, all patients gradually progress to acquired resistance via diverse mechanisms. Akt3 overexpression but not Akt1/2 is one of the found molecular events that mediate osimertinib (1) resistance in NSCLC patients. Here, we report 12l as the first bona fide isoform-selective Akt3 degrader which potently induced proteasomal degradation of the target both in vitro and in vivo, whereas its effects on Akt1/2 were minimal. Using 12l as a tool, non-canonical function of Akt3 was validated to contribute greatly to survival of 1-resistant H1975OR NSCLC cells. Degrader 12l potently suppressed the growth of H1975OR as well as several NSCLC cell lines with low nanomolar IC50 values and demonstrated promising in vivo antitumor efficacy in nude mice bearing H1975OR or PC9 NSCLC xenograft models. Selective degradation of Akt3 may be considered as a novel strategy for human cancer therapy.
Collapse
Affiliation(s)
- Fang Xu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China.,The First Affiliated Hospital (Huaqiao Hospital), Jinan University, Guangzhou 510632, China
| | - Xin Zhang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China.,The First Affiliated Hospital (Huaqiao Hospital), Jinan University, Guangzhou 510632, China
| | - Zhipeng Chen
- MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
| | - Sheng He
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Jing Guo
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Lei Yu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Yongjin Wang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Caiyun Hou
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Hawaa Ai-Furas
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Zongyao Zheng
- MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
| | - Jeff B Smaill
- Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland 1142, New Zealand
| | - Adam V Patterson
- Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland 1142, New Zealand
| | - Zhi-Min Zhang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China
| | - Liang Chen
- MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
| | - Xiaomei Ren
- State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 210530, China
| | - Ke Ding
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of PR China, College of Pharmacy, Jinan University, Guangzhou 510632, China.,The First Affiliated Hospital (Huaqiao Hospital), Jinan University, Guangzhou 510632, China.,State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 210530, China
| |
Collapse
|
4
|
Zhuang T, Xiong J, Ren X, Liang L, Qi Z, Zhang S, Du W, Chen Y, Liu X, Zhang G. Benzylaminofentanyl derivates: Discovery of bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced adverse effects. Eur J Med Chem 2022; 241:114649. [DOI: 10.1016/j.ejmech.2022.114649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 07/28/2022] [Accepted: 07/30/2022] [Indexed: 11/04/2022]
|
5
|
Li S, Si H, Song X, Lei C, He X, Wang J, Liu Y, Zhou Y, Song JG, Peng L, Tang X, Chan S, Ren X, Tu Z, Li Z, Wang Z, Zhang Z, Ding K. Discovery of Hexahydrofuro[3,2- b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant. J Med Chem 2022; 65:10674-10690. [PMID: 35860875 DOI: 10.1021/acs.jmedchem.2c00922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Janus kinase 3 (JAK3) is a potential target for the treatment of hematological malignancies. Herein, we report the discovery of a series of new orally bioavailable irreversible JAK3 kinase inhibitors. The representative compound 12n potently inhibited JAK3 kinase activity with an IC50 value of 1.2 nM and was more than 900-fold selective over JAK1, JAK2, and Tyk2. Cell-based assays revealed that 12n significantly suppressed phosphorylation of JAK3 and the downstream effectors STAT3/5 and also robustly restrained proliferation of BaF3 cells transfected with JAK3M511I activating mutation and human leukemia U937 cells harboring JAK3M511I with IC50 values of 22.9 and 20.2 nM, respectively. More importantly, 12n showed reasonable pharmacokinetic (PK) properties, and oral administration of 12n at a dose of 50 mg/kg twice daily led to tumor regression in a U937 cell inoculated xenograft mouse model. Thus, 12n represents a promising lead compound for further optimization to discover new therapeutic agents for hematological malignancies.
Collapse
Affiliation(s)
- Shan Li
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Hongfei Si
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Xiaojuan Song
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou 510530, China
| | - Chong Lei
- State Key Laboratory of Bioorganic Chemistry and Natural Products, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Road, Shanghai 200032, China
| | - Xiaoqiang He
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Jie Wang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Yiling Liu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Yang Zhou
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Jian-Guo Song
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Lijie Peng
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Xia Tang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Shingpan Chan
- Guangzhou Lixin Pharmaceuticals, Guangzhou 510530, China
| | - Xiaomei Ren
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Zhengchao Tu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou 510530, China
| | - Zhengqiu Li
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Zhen Wang
- State Key Laboratory of Bioorganic Chemistry and Natural Products, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Road, Shanghai 200032, China
| | - Zhang Zhang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China
| | - Ke Ding
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.,State Key Laboratory of Bioorganic Chemistry and Natural Products, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Road, Shanghai 200032, China.,The First Affiliated Hospital (Huaqiao Hospital), Jinan University, #601 Huangpu Avenue West, Guangzhou 510632, China.,Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China
| |
Collapse
|
6
|
Yadav TT, Moin Shaikh G, Kumar MS, Chintamaneni M, YC M. A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship. Front Chem 2022; 10:861288. [PMID: 35769445 PMCID: PMC9234326 DOI: 10.3389/fchem.2022.861288] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 04/28/2022] [Indexed: 01/05/2023] Open
Abstract
Epidermal growth factor receptor (EGFR) belongs to the family of tyrosine kinase that is activated when a specific ligand binds to it. The EGFR plays a vital role in the cellular proliferation process, differentiation, and apoptosis. In the case of cancer, EGFR undergoes uncontrolled auto-phosphorylation that results in increased cellular proliferation and decreased apoptosis, causing cancer promotion. From the literature, it shows that pyrimidine is one of the most commonly studied heterocycles for its antiproliferative activity against EGFR inhibition. The authors have collated some interesting results in the heterocycle-fused pyrimidines that have been studied using different cell lines (sensitive and mutational) and in animal models to determine their activity and potency. It is quite clear that the fused systems are highly effective in inhibiting EGFR activity in cancer cells. Therefore, the structure–activity relationship (SAR) comes into play in determining the nature of the heterocycle and the substituents that are responsible for the increased activity and toxicity. Understanding the SAR of heterocycle-fused pyrimidines will help in getting a better overview of the molecules concerning their activity and potency profile as future EGFR inhibitors.
Collapse
Affiliation(s)
| | | | | | | | - Mayur YC
- *Correspondence: Mayur YC, mayur
| |
Collapse
|
7
|
Li S, Zhang T, Zhu SJ, Lei C, Lai M, Peng L, Tong L, Pang Z, Lu X, Ding J, Ren X, Yun CH, Xie H, Ding K. Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR T790M/C797S Mutants. ACS Med Chem Lett 2022; 13:196-202. [PMID: 35178175 PMCID: PMC8842099 DOI: 10.1021/acsmedchemlett.1c00555] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Accepted: 01/05/2022] [Indexed: 12/14/2022] Open
Abstract
A series of brigatinib derivatives were designed and synthesized as new potent and selective EGFRT790M/C797S inhibitors. One of the most potent and selective compounds 18k strongly suppressed the EGFRL858R/T790M/C797S and EGFR19Del/T790M/C797S kinases with IC50 values of 0.7 and 3.6 nM, respectively, which were over 54-fold more potent than the lead compound. 18k also demonstrated promising EGFRT790M/C797S mutant selectivity, and was 94-fold less potent against the wild type EGFR. A cocrystal structure of EGFRT790M/C797S with a close derivative 18f was solved to provide insight on the inhibitor's binding mode. Moreover, compound 18k was orally bioavailable and demonstrated highly desirable PK properties, making it a promising lead compound for further structural optimization.
Collapse
Affiliation(s)
- Shan Li
- International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry of Education (MOE) of China,
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511436, China
| | - Tao Zhang
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Su-Jie Zhu
- Institute
of Translational Medicine, The Affiliated Hospital of Qingdao University,
College of Medicine, Qingdao University, Qingdao 266021, China
| | - Chong Lei
- State
Key Laboratory of Bioorganic Chemistry and Natural Products, Shanghai Institute of Organic Chemistry, Chinese Academy
of Sciences, 345 Lingling
Road, Shanghai 200032, China
| | - Mengzhen Lai
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Lijie Peng
- International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry of Education (MOE) of China,
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511436, China
| | - Linjiang Tong
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Zilu Pang
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Xiaoyun Lu
- International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry of Education (MOE) of China,
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511436, China
| | - Jian Ding
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Xiaomei Ren
- International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry of Education (MOE) of China,
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511436, China,
| | - Cai-Hong Yun
- Department
of Biochemistry and Biophysics, Institute of Systems Biomedicine,
School of Basic Medical Sciences, Peking
University Health Science Center, Beijing 100191, China,
| | - Hua Xie
- Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China,Zhongshan
Institute for Drug Discovery, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China,
| | - Ke Ding
- International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry of Education (MOE) of China,
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511436, China,State
Key Laboratory of Bioorganic Chemistry and Natural Products, Shanghai Institute of Organic Chemistry, Chinese Academy
of Sciences, 345 Lingling
Road, Shanghai 200032, China,
| |
Collapse
|
8
|
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorg Med Chem 2022; 56:116614. [DOI: 10.1016/j.bmc.2022.116614] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 12/15/2021] [Accepted: 01/06/2022] [Indexed: 12/19/2022]
|
9
|
Zhang X, Xu F, Tong L, Zhang T, Xie H, Lu X, Ren X, Ding K. Design and synthesis of selective degraders of EGFR L858R/T790M mutant. Eur J Med Chem 2020; 192:112199. [PMID: 32171162 DOI: 10.1016/j.ejmech.2020.112199] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 02/12/2020] [Accepted: 02/28/2020] [Indexed: 10/24/2022]
Abstract
A series of PROTAC (proteolysis targeting chimera) based selective EGFRL858R/T790M (leucine 858 to arginine 858 mutation and threonine 790 to methionine 790) mutant degraders were designed and synthesized. One of the most potent compounds, 14o, effectively and selectively degraded EGFRL858R/T790M with an DC50 value of 5.9 nM, while did not show obvious effect on the wild-type protein. Further mechanism investigation revealed that the degradation was mediated by ubiquitin proteasome pathway. Compound 14o could be utilized as an initial lead molecule for development of new EGFRL858R/T790M degrader based therapy.
Collapse
Affiliation(s)
- Xin Zhang
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of China, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China
| | - Fang Xu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of China, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China
| | - Linjiang Tong
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Tao Zhang
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Hua Xie
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Xiaoyun Lu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of China, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China
| | - Xiaomei Ren
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of China, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
| | - Ke Ding
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of China, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
| |
Collapse
|
10
|
Lu X, Zhang T, Zhu SJ, Xun Q, Tong L, Hu X, Li Y, Chan S, Su Y, Sun Y, Chen Y, Ding J, Yun CH, Xie H, Ding K. Discovery of JND3229 as a New EGFR C797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett 2018; 9:1123-1127. [PMID: 30429956 DOI: 10.1021/acsmedchemlett.8b00373] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 10/08/2018] [Indexed: 12/21/2022] Open
Abstract
EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clinical need" for nonsmall cell lung cancer patients. The pyrimidopyrimidinone derivative JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency. It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells. A high-resolution X-ray crystallographic structure was also determined to elucidate the interactions between JND3229 and EGFRT790M/C797S. Our study provides an important structural and chemical basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.
Collapse
Affiliation(s)
- Xiaoyun Lu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Tao Zhang
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
- School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China
- School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
| | - Su-Jie Zhu
- Department of Biophysics and Peking University Institute of Systems Biomedicine, Peking University Health Science Center, Beijing 100191, China
| | - Qiuju Xun
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Lingjiang Tong
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Xianglong Hu
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Yan Li
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Shingpan Chan
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Yi Su
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Yiming Sun
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Yi Chen
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Jian Ding
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Cai-Hong Yun
- Department of Biophysics and Peking University Institute of Systems Biomedicine, Peking University Health Science Center, Beijing 100191, China
| | - Hua Xie
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China
| | - Ke Ding
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| |
Collapse
|
11
|
Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Bioorg Med Chem 2018; 26:3619-3633. [DOI: 10.1016/j.bmc.2018.05.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 05/21/2018] [Accepted: 05/23/2018] [Indexed: 01/09/2023]
|
12
|
Hao Y, Lyu J, Qu R, Tong Y, Sun D, Feng F, Tong L, Yang T, Zhao Z, Zhu L, Ding J, Xu Y, Xie H, Li H. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J Med Chem 2018; 61:5609-5622. [DOI: 10.1021/acs.jmedchem.8b00346] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Yongjia Hao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
- School of Pharmacy, Guizhou University of Chinese Medicine, Guiyang 550025, China
| | - Jiankun Lyu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Rong Qu
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yi Tong
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Deheng Sun
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Fang Feng
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Linjiang Tong
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Tingyuan Yang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zhenjiang Zhao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Jian Ding
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yufang Xu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Hua Xie
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| |
Collapse
|
13
|
Xun Q, Zhang Z, Luo J, Tong L, Huang M, Wang Z, Zou J, Liu Y, Xu Y, Xie H, Tu ZC, Lu X, Ding K. Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. J Med Chem 2018; 61:2353-2371. [PMID: 29499108 DOI: 10.1021/acs.jmedchem.7b01612] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Qiuju Xun
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China
| | - Zhang Zhang
- School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Jinfeng Luo
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Linjiang Tong
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
| | - Minhao Huang
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China
| | - Zhen Wang
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Jian Zou
- School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Yingqiang Liu
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
- School of Life Sciences, Shanghai University, No. 99 Shangda Road, Shanghai 200444, China
| | - Yong Xu
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Hua Xie
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
| | - Zheng-Chao Tu
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Xiaoyun Lu
- School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
| | - Ke Ding
- State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China
- School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
- Guangzhou City Key Laboratory of Precision Chemical Drug Development, Guangzhou 510632, China
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People’s Republic of China, Guangzhou 510632, China
| |
Collapse
|
14
|
Zhang H, Wang J, Shen Y, Wang HY, Duan WM, Zhao HY, Hei YY, Xin M, Cao YX, Zhang SQ. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. Eur J Med Chem 2018; 148:221-237. [DOI: 10.1016/j.ejmech.2018.02.051] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 02/14/2018] [Accepted: 02/14/2018] [Indexed: 12/19/2022]
|
15
|
Chen D, Guo D, Yan Z, Zhao Y. Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. MEDCHEMCOMM 2017; 9:244-253. [PMID: 30108918 DOI: 10.1039/c7md00571g] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Accepted: 12/10/2017] [Indexed: 12/13/2022]
Abstract
The success of acrylamide-containing drugs in treating cancers has spurred a passion to search for acrylamide bioisosteres. In our endeavour, we have identified that an allenamide group can be a reactive bioisostere of the acrylamide group. In our development of allenamide-containing compounds, we found that the most potent compound, 14, inhibited the kinase activities of both T790M/L858R double mutant and wild type EGFR in a low nM range. 14 also inhibited the growth of NCI-H1975 lung cancer cells at IC50 = 33 nM, which is comparable to that of acrylamide-containing osimertinib. The western blot analysis showed that the phosphorylation of EGFR, AKT, and ERK1/2 was simultaneously inhibited in a dose-dependent manner when NCI-H1975 cells were treated with 14. By measuring the conjugate addition product formed by 14 and GSH, we obtained a reaction rate constant of 302.5 × 10-3 min-1, which is about 30-fold higher than that of osimertinib. Taken together, our data suggest that the allenamide-containing compounds inhibited EGFR kinases through covalent modifications. Our study indicates that the allenamide group could serve as an alternative electrophilic warhead in the design of targeted covalent inhibitors, and this bioisostere replacement may have broad applications in medicinal chemistry.
Collapse
Affiliation(s)
- Deheng Chen
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China . .,University of Chinese Academy of Sciences , Beijing 100049 , China
| | - Dexiang Guo
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| | - Ziqin Yan
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| | - Yujun Zhao
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| |
Collapse
|
16
|
A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. Future Med Chem 2017; 9:693-704. [DOI: 10.4155/fmc-2016-0222] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The EGFR is one of the most popular targets for anticancer therapies and many drugs, such as erlotinib and gefitinib, have got enormous success in clinical treatments of cancer in past decade. However, the efficacy of these agents is often limited because of the quick emergence of drug resistance. Fundamental structure researches of EGFR in recent years have generally elucidated the mechanism of drug resistance. In this review, based on systematic resolution of full structures of EGFR and their variants via single crystal x-ray crystallography, the working and drug resistance mechanism of EGFR-targeted drugs are fully illustrated. Moreover, new strategies for avoiding EGFR drug resistance in cancer treatments are also discussed.
Collapse
|
17
|
Yu L, Huang M, Xu T, Tong L, Yan XE, Zhang Z, Xu Y, Yun C, Xie H, Ding K, Lu X. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties. Eur J Med Chem 2016; 126:1107-1117. [PMID: 28033579 DOI: 10.1016/j.ejmech.2016.12.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/24/2016] [Accepted: 12/02/2016] [Indexed: 12/24/2022]
Abstract
Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790M inhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790M kinase and inhibited the proliferation of H1975 cells with IC50 values of 2.0 nM and 40 nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCIH1975 cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.
Collapse
Affiliation(s)
- Lei Yu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China; University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
| | - Minhao Huang
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China; University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
| | - Tianfeng Xu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China; University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
| | - Linjiang Tong
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
| | - Xiao-E Yan
- Peking University Institute of Systems Biomedicine and Department of Biophysics, Peking University Health Science Center, Beijing 100191, China
| | - Zhang Zhang
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Yong Xu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China
| | - Caihong Yun
- Peking University Institute of Systems Biomedicine and Department of Biophysics, Peking University Health Science Center, Beijing 100191, China
| | - Hua Xie
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
| | - Ke Ding
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China; School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China.
| | - Xiaoyun Lu
- School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China.
| |
Collapse
|
18
|
Hao Y, Wang X, Zhang T, Sun D, Tong Y, Xu Y, Chen H, Tong L, Zhu L, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J Med Chem 2016; 59:7111-24. [DOI: 10.1021/acs.jmedchem.6b00403] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Yongjia Hao
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Xia Wang
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Tao Zhang
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Deheng Sun
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Yi Tong
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Yuqiong Xu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Haiyang Chen
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Linjiang Tong
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Lili Zhu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Zhenjiang Zhao
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Zhuo Chen
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Jian Ding
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Hua Xie
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Yufang Xu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Honglin Li
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| |
Collapse
|
19
|
Yang W, Ye S, Schmidt Y, Stamos D, Yu JQ. Ligand-Promoted C(sp(3) )-H Olefination en Route to Multi-functionalized Pyrazoles. Chemistry 2016; 22:7059-62. [PMID: 26991450 PMCID: PMC4944759 DOI: 10.1002/chem.201600704] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Indexed: 12/29/2022]
Abstract
A Pd-catalyzed/N-heterocycle-directed C(sp(3) )-H olefination has been developed. The monoprotected amino acid ligand (MPAA) is found to significantly promote Pd-catalyzed C(sp(3) )-H olefination for the first time. Cu(OAc)2 instead of Ag(+) salts are used as the terminal oxidant. This reaction provides a useful method for the synthesis of alkylated pyrazoles.
Collapse
Affiliation(s)
- Weibo Yang
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Shengqing Ye
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Yvonne Schmidt
- Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd., San Diego, CA, 92121, USA
| | - Dean Stamos
- Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd., San Diego, CA, 92121, USA
| | - Jin-Quan Yu
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA.
| |
Collapse
|
20
|
Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. Future Med Chem 2016; 8:853-78. [DOI: 10.4155/fmc-2016-0019] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Deregulation of EGFR is involved in the development of many cancers. The inhibition of EGFR kinase activity has been clinically validated as a promising approach for the treatment of non-small-cell lung cancer (NSCLC). However, all NSCLC patients who initially benefited from first-generation EGFR inhibitors eventually develop drug resistance. A point mutation at the gatekeeper position, T790M in EGFR kinase domain accounts for more than 50% of acquired resistance. Therefore, second- and third-generation EGFR inhibitors have been developed to overcome the resistance conferred by the gatekeeper mutation. This review has highlighted recent advances in overcoming acquired resistance for the development of each generation of EGFR inhibitors along with their potential issues, and urgent quest for the development of new generation of EGFR inhibitors.
Collapse
|
21
|
Song Z, Ge Y, Wang C, Huang S, Shu X, Liu K, Zhou Y, Ma X. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. J Med Chem 2016; 59:6580-94. [PMID: 26882288 DOI: 10.1021/acs.jmedchem.5b00840] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine(790)-to-methionine(790) (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clinical efficacy. Recently, a large number of small-molecule inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified. In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S. FDA in 2014. We hope that this review on the small-molecule EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-containing EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochemical properties.
Collapse
Affiliation(s)
- Zhendong Song
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Yang Ge
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Changyuan Wang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Shanshan Huang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Xiaohong Shu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Kexin Liu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Youwen Zhou
- Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC, V5Z 4E8, Canada
| | - Xiaodong Ma
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| |
Collapse
|
22
|
Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KKC, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr STM, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem 2016; 59:2005-24. [PMID: 26756222 DOI: 10.1021/acs.jmedchem.5b01633] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.
Collapse
Affiliation(s)
- Hengmiao Cheng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sajiv K Nair
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Brion W Murray
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Chau Almaden
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Simon Bailey
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sangita Baxi
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Doug Behenna
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sujin Cho-Schultz
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Deepak Dalvie
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Dac M Dinh
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Martin P Edwards
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jun Li Feng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Rose Ann Ferre
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ketan S Gajiwala
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Michelle D Hemkens
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Amy Jackson-Fisher
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Mehran Jalaie
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ted O Johnson
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Robert S Kania
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Susan Kephart
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jennifer Lafontaine
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Beth Lunney
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Kevin K-C Liu
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Zhengyu Liu
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jean Matthews
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Asako Nagata
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sherry Niessen
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Martha A Ornelas
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Suvi T M Orr
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Mason Pairish
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Simon Planken
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shijian Ren
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Daniel Richter
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Kevin Ryan
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Neal Sach
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Hong Shen
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Tod Smeal
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jim Solowiej
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Scott Sutton
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Khanh Tran
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Elaine Tseng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - William Vernier
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Marlena Walls
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shuiwang Wang
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Scott L Weinrich
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shuibo Xin
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Haiwei Xu
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Min-Jean Yin
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Michael Zientek
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ru Zhou
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - John C Kath
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| |
Collapse
|
23
|
Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St. Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett 2015; 6:987-92. [PMID: 26396685 DOI: 10.1021/acsmedchemlett.5b00193] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 07/27/2015] [Indexed: 01/26/2023] Open
Abstract
In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido[2,3-d]pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound 24 which potently inhibits gefitinib-resistant EGFR(L858R,T790M) with 100-fold selectivity over wild-type EGFR. Compound 24 displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR(L858R,T790M) driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR.
Collapse
Affiliation(s)
- Ryan P. Wurz
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Liping H. Pettus
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kate Ashton
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - James Brown
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jian Jeffrey Chen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Brad Herberich
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Fang-Tsao Hong
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Essa Hu-Harrington
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tom Nguyen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David J. St. Jean
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Seifu Tadesse
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David Bauer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Michele Kubryk
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jinghui Zhan
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Keegan Cooke
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Petia Mitchell
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kristin L. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Faye Hsieh
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dean Hickman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nataraj Kalyanaraman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tian Wu
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Darren L. Reid
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Edward K. Lobenhofer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dina A. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nancy Everds
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Roberto Guzman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew T. Parsons
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Simon J. Hedley
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jason Tedrow
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Oliver R. Thiel
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Matthew Potter
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Robert Radinsky
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Pedro J. Beltran
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew S. Tasker
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| |
Collapse
|
24
|
Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. DRUG DESIGN DEVELOPMENT AND THERAPY 2015; 9:3837-51. [PMID: 26229444 PMCID: PMC4517520 DOI: 10.2147/dddt.s85357] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The epidermal growth factor receptor (EGFR) family has been validated as a successful antitumor drug target for decades. Known EGFR inhibitors were exposed to distinct drug resistance against the various EGFR mutants within non-small-cell lung cancer (NSCLC), particularly the T790M mutation. Although so far a number of studies have been reported on the development of third-generation EGFR inhibitors for overcoming the resistance issue, the design procedure largely depends on the intuition of medicinal chemists. Here we retrospectively make a detailed analysis of the 42 EGFR family protein crystal complexes deposited in the Protein Data Bank (PDB). Based on the analysis of inhibitor binding modes in the kinase catalytic cleft, we identified a potent EGFR inhibitor (compound A-10) against drug-resistant EGFR through fragment-based drug design. This compound showed at least 30-fold more potency against EGFR T790M than the two control molecules erlotinib and gefitinib in vitro. Moreover, it could exhibit potent HER2 inhibitory activities as well as tumor growth inhibitory activity. Molecular docking studies revealed a structural basis for the increased potency and mutant selectivity of this compound. Compound A-10 may be selected as a promising candidate in further preclinical studies. In addition, our findings could provide a powerful strategy to identify novel selective kinase inhibitors on the basis of detailed kinase–ligand interaction space in the PDB.
Collapse
Affiliation(s)
- Wei Liu
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Jin-Feng Ning
- The Thoracic Surgery Department, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Qing-Wei Meng
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Jing Hu
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Yan-Bin Zhao
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Chao Liu
- General Surgery Department, Mudanjiang Guanliju Central Hospital, Mishan, Heilongjiang Province, People's Republic of China
| | - Li Cai
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| |
Collapse
|
25
|
Xu T, Peng T, Ren X, Zhang L, Yu L, Luo J, Zhang Z, Tu Z, Tong L, Huang Z, Lu X, Geng M, Xie H, Ding J, Ding K. C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00208g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
C5-substituted pyrido[2,3-d]pyrimidin-7-ones were discovered as highly potent and specific inhibitors targeting the clinical resistance-related EGFRL858R/T790M mutant.
Collapse
|
26
|
Ren YJ, Wang ZC, Zhang X, Qiu HY, Wang PF, Gong HB, Jiang AQ, Zhu HL. EGFR/HER-2 inhibitors: synthesis, biological evaluation and 3D-QSAR analysis of dihydropyridine-containing thiazolinone derivatives. RSC Adv 2015. [DOI: 10.1039/c4ra10606g] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of dihydropyridin containing thiazolinone derivatives (4a–4r) have been designed, synthesized and their biological activities were also evaluated as potential EGFR and HER-2 kinase inhibitors and tumor cell antiproliferation.
Collapse
Affiliation(s)
- Yu-Jia Ren
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| | - Zhong-Chang Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| | - Xin Zhang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| | - Han-Yue Qiu
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| | - Peng-Fei Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| | | | - Ai-Qin Jiang
- Medical School of Nanjing University
- Nanjing 210093
- People’s Republic of China
| | - Hai-Liang Zhu
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- Nanjing 210093
- People’s Republic of China
| |
Collapse
|
27
|
Zhang S, Tan J, Lai Z, Li Y, Pang J, Xiao J, Huang Z, Zhang Y, Ji H, Lai Y. Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-activating enzyme inhibitors. J Chem Inf Model 2014; 54:1785-97. [PMID: 24857708 DOI: 10.1021/ci5002058] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The NEDD8-activating enzyme (NAE) is an emerging target for cancer therapy, which regulates the degradation and turnover of a variety of cancer-related proteins by activating the cullin-RING E3 ubiquitin ligases. Among a limited number of known NAE inhibitors, the covalent inhibitors have demonstrated the most potent efficacy through their covalently linked adducts with NEDD8. Inspired by this unique mechanism, in this study, a novel combined strategy of virtual screening (VS) was adopted with the aim to identify diverse covalent inhibitors of NAE. To be specific, a docking-enabled pharmacophore model was first built from the possible active conformations of chosen covalent inhibitors. Meanwhile, a dynamic structure-based phamacophore was also established based on the snapshots derived from molecular dynamic simulation. Subsequent screening of a focused ZINC database using these pharmacophore models combined with covalent docking discovered three novel active compounds. Among them, compound LZ3 exhibited the most potent NAE inhibitory activity with an IC50 value of 1.06 ± 0.18 μM. Furthermore, a cell-based washout experiment proved the proposed covalent binding mechanism for compound LZ3, which confirmed the successful application of our combined VS strategy, indicating it may provide a viable solution to systematically discover novel covalent ligands.
Collapse
Affiliation(s)
- Shengping Zhang
- State Key Laboratory of Natural Medicines, ‡Center of Drug Discovery, §Department of Pharmacology, and ∥School of Pharmacy, China Pharmaceutical University , Nanjing 210009, Jiangsu, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|